When a patient on an antipsychotic develops severe anxiety, the reflex is to treat the anxiety. But in a meaningful share of those cases the "anxiety" is actually akathisia — a drug-induced movement disorder whose cardinal feature is a tormenting inner restlessness. Learning how to differentiate akathisia from anxiety and agitation is a safety skill: misreading it leads to dose escalation, polypharmacy, or wrongly labelling the patient as non-adherent.
This guide gives you a practical framework — onset, triggers, description, objective signs — plus a comparison table and the treatment clues that separate the two in clinic and in exams.
What akathisia actually is
Akathisia (from the Greek for "without sitting") is a dystonic reaction to dopamine D2 blockade, most often triggered by antipsychotics — typicals carry higher risk, but atypicals such as risperidone and aripiprazole cause it too. It can also follow dopamine-depleting drugs (metoclopramide, prochlorperazine) and, less commonly, antidepressant dose rises.
Three features define it:
- Subjective drive to move — an inner tension the patient describes as unbearable sitting still, pacing being the only relief.
- Temporal link to exposure — onset days to weeks after starting or up-titrating a dopamine antagonist, or after a dose increase.
- Symptom-dose relationship — improves when the offending drug is reduced or stopped, worsens on rechallenge.
Anxiety and agitation: different machinery
Anxiety is anticipatory — worry about something, present or future, with a cognitive content you can elicit ("I'm worried about my mother's results"). Agitation is an observable state of heightened motor and psychic activity: loud, pressured, disorganised, often without a clear internal trigger.
Akathisia borrows features from both. Patients report "anxiety" with no worry content, describe panic-like dread, and appear objectively restless — pacing, shifting weight, crossing and uncrossing legs. That overlap is exactly why it hides in plain sight.
How to differentiate akathisia from anxiety and agitation
Use four axes: history of exposure, timing, the patient's own description, and what happens on examination.
| Feature | Akathisia | Anxiety | Agitation |
|---|---|---|---|
| Typical trigger | Antipsychotic start/dose rise | Psychosocial stress, GAD | Delirium, mania, intoxication |
| Onset | Days–weeks after exposure | Gradual or situational | Acute |
| Core description | "I can't sit still inside" | Worry with identifiable content | Explosive, disorganised activity |
| Movement | Continuous rocking, leg-shifting | Fidgeting, intermittent | Gross, purposeless, may be aggressive |
| Response to reassurance | Minimal — physical restlessness persists | Partial | Usually none |
| Effect of dose reduction | Improves over days–weeks | No relationship | No relationship |
A quick bedside differentiator: ask the patient to sit still for two minutes. The anxious person settles once reassured; the akathisic patient cannot — the restlessness is motor, not motivated.
Severity and recognition tools
Standardise assessment with the Barnes Akathisia Rating Scale: subjective awareness of restlessness (item 1), objective visible restlessness (item 2), awareness of distress (item 3), and global severity (item 4). A score of 2 or above on the global item marks clinically significant akathisia requiring action.
Red flags in the history:
- Panic attacks that started only after an antipsychotic dose increase
- "My anxiety is worse than my psychosis" within weeks of a switch
- Suicidality or self-harm emerging shortly after exposure — akathisia carries a recognised suicide risk, which is why it is never a benign finding
Management: treat the cause, not the label
The definitive move is reducing or stopping the causative agent and switching to a lower-risk antipsychotic (quetiapine or clozapine carry comparatively low akathisia risk — see the concept library for antipsychotic pharmacology notes).
When the antipsychotic must continue, adjuncts have trial support:
- Propranolol (β-blocker) — commonly first-line, typical doses 20–80 mg/day
- Benzodiazepines — short-term relief while the dose change takes effect
- Anticholinergics (benztropine, procyclidine) — useful when akathisia overlaps with other extrapyramidal effects; less reliable as monotherapy
- Mirtazapine (5-HT2A antagonism) — an evidence-supported alternative
Exam trap
Vignettes describe "worsening anxiety and insomnia" a fortnight after starting risperidone, with a patient who paces the room and denies any worry content. The tested answer is akathisia, and the correct next step is dose reduction or an adjunct like propranolol — not switching to an antidepressant. If a question offers "increase the antipsychotic for breakthrough anxiety", that option is almost always wrong.
Special situations: antidepressants, tardive akathisia and vulnerable groups
Akathisia is not exclusive to antipsychotics. SSRIs and SNRIs can produce it, typically after a dose increase, through serotonergic modulation of dopaminergic pathways — this is the most plausible mechanism behind SSRI-induced activation and agitation states. Deprescribing or dose reduction follows the same logic as with antipsychotics, and mirtazapine has a reasonable evidence base here precisely because of its 5-HT2A antagonism.
Tardive akathisia — persisting or emerging after prolonged exposure — behaves differently from the acute form: it is less reliably reversible, movement-related discomfort may be misattributed to psychiatric deterioration, and rechallenge with a higher-potency agent usually worsens it. Recognition matters because the wrong response (adding another antipsychotic or upping the existing one) deepens the problem.
Vulnerable groups need extra suspicion. Older patients on metoclopramide for nausea, adolescents started on stimulants or antidepressants, and patients moved between brands of the same antipsychotic (bioequivalence differences are real) all represent classic presentations. In each, the sequence — new restlessness, new drug or dose change, symptom-dose relationship — should trigger an immediate medication review before any psychiatric relabelling occurs.
Finally, document the reasoning. A note reading "severe inner restlessness, onset 10 days after risperidone 4→6 mg, Barnes 3, no worry content — plan: dose reduction, propranolol 20 mg TDS" is both better medicine and a clear audit trail; it also becomes the reference pattern students learn from when they inherit your patients.
Frequently asked questions
How do you tell akathisia apart from anxiety in a patient on antipsychotics?
Anchor on exposure and description: akathisia follows a dopamine antagonist start or dose increase, features an internal drive to move with no worry content, and fails to settle with reassurance; anxiety has identifiable cognitive content and no dose relationship. A Barnes scale score of 2+ and improvement after dose reduction confirm the distinction.
Can akathisia cause panic attacks?
Yes. Akathisia commonly presents as panic-like episodes with autonomic arousal and free-floating dread, which is why new-onset "panic" shortly after an antipsychotic dose change should trigger a movement-disorder review rather than automatic antidepressant or benzodiazepine treatment of primary anxiety.
How long does akathisia take to resolve after stopping the drug?
Acute akathisia usually improves within days to two weeks of dose reduction or cessation; tardive forms may take weeks to months. The symptom-dose relationship — improvement on dechallenge — is itself diagnostic evidence.
Which antipsychotics carry the lowest akathisia risk?
Quetiapine and clozapine have the lowest rates owing to fast dissociation and potent 5-HT2A blockade; risperidone, aripiprazole and haloperidol are higher risk. This profile is a recurring exam comparison across MRCPsych and USMLE psychopharmacology questions.
Key takeaways
- Akathisia = inner restlessness from D2 blockade; the patient cannot sit still even when reassured.
- Temporal link to antipsychotic exposure plus a symptom-dose relationship are the diagnostic anchors.
- Misreading it as anxiety leads to dose escalation and missed suicide risk — always ask about new restlessness after dose changes.
- Barnes Akathisia Rating Scale ≥2 global = act: reduce the dose, add propranolol, or switch.
- Propranolol, benzodiazepines, anticholinergics and mirtazapine are the evidence-supported adjuncts.
Differentiating movement disorders from psychiatric symptoms is exactly the kind of discrimination Preppsy drills daily — try a psychiatry MCQ mock exam to test yours.
Cover image: “Akathisia or Anxiety? (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.
